CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. - Wikidata - awgldk - TriplyDB

CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.

CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.

http://www.wikidata.org/entity/Q37892578

about

Novel immunotherapeutic approaches to the treatment of urothelial carcinoma Evolving immunotherapy strategies in urothelial cancer Optimizing dendritic cell-based approaches for cancer immunotherapy Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review.Trial Watch: Experimental Toll-like receptor agonists for cancer therapy Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches.Nonmuscle invasive bladder cancer: a primer on immunotherapy.Targeting CLEC9A delivers antigen to human CD141(+) DC for CD4(+) and CD8(+)T cell recognition Novel molecular targets for the therapy of urothelial carcinoma.Targeting antigens to dendritic cell receptors for vaccine development Dendritic cell-targeted vaccines.Toll-like receptor agonists shape the immune responses to a mannose receptor-targeted cancer vaccine Future directions in bladder cancer immunotherapy: towards adaptive immunity.Vesigenurtacel-L (HS-410) in the management of high-grade nonmuscle invasive bladder cancer.CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses.Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccines New therapies in nonmuscle invasive bladder cancer treatment.Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.Investigation of factors influencing the immunogenicity of hCG as a potential cancer vaccine.Significant Immunohistochemical Expression of Human Chorionic Gonadotropin in High-Grade Osteosarcoma is Rare, but May Be Associated with Clinically Elevated Serum Levels Vaccines in clinical trials: cancer

P2860

Q26744347-91280686-2547-46D4-9859-0883626437BE Q26823557-4D5F3804-E3FB-47AD-AD48-81E124691011 Q34637535-F7ABE76B-0582-4D7B-8DC9-B53C856BEC1D Q34993621-1BB3B264-FECA-48C2-AAC2-6A07D87E540B Q36194849-1709C075-9999-4BFF-AFED-A532E0F437CE Q36589753-B18A5DEA-0ACD-4889-8601-5CE062E1E489 Q37094072-7BDA2B0D-FE12-4D91-A96B-E408B2A42489 Q37277188-52F71498-11AF-4300-95EF-F0DB0E34CFE3 Q38003195-72626402-7E15-4815-AEB9-906F80D0929E Q38162446-0921B16C-A7E0-4986-B9B8-0B1E4F961CF8 Q38218671-C24D3E35-536A-416E-98BB-7B274432EFEC Q38303372-FBB0A886-E332-47F6-9E62-6AFB65FD637A Q38727522-5BD5D7A5-D618-4FD4-AA4A-118F8A314442 Q38823147-D3E8BE62-9670-4354-913A-464C5A8CAC9F Q39448429-B5464B40-0680-4023-AFB8-5A7BCD809C4D Q39448911-C7673B91-1057-4EBF-8181-75BD4663B60E Q49519778-4D0DC8F3-CDC6-48A7-9232-5C1DEB688D88 Q50457532-BACF55C2-5517-4151-A332-4B1ED3EE04CF Q52722908-1A140525-C417-4D89-A4D4-BDF085235B15 Q57505097-8CA41600-E036-4B6E-8019-5B5A333A83A6 Q57594208-A3CE2303-EAEF-4F84-89A4-5C6091607804

P2860

CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.

http://www.wikidata.org/entity/Q37892578

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.

@en

CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.

@nl

type

label

CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.

@en

CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.

@nl

prefLabel

CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.

@en

CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.

@nl

P1433

Q37892578-DCB0EBF7-9058-4642-A7AC-933AA4DA6DB8

P1476

Q37892578-409B3BD0-7860-4C51-BD14-A338C5BBE824

P2093

Q37892578-1F1AED19-60CA-49DC-A33B-8EBE8314CB80

Q37892578-35C86B32-04F2-45ED-880F-178F014E7F5C

Q37892578-594BFFF7-3A64-4B50-9C8C-D4DDA8FBA010

Q37892578-867D5CAD-103E-466D-8CEF-DC060D367448

Q37892578-AB2BDB66-636F-4777-A201-7B337BD96130

Q37892578-B6C98D0B-D9E5-4B7F-8B4A-ABE1E33FC210

P2860

Q37892578-0D34EE9C-6603-4CC1-8EA8-8FC9A5105E35

Q37892578-106F9613-2DAF-40EC-9163-00C9B7DBC344

Q37892578-189C4D0F-46A2-4D60-AAB5-FD43761CA4CA

Q37892578-1DD5A83E-3566-4498-B55C-73521037EF90

Q37892578-22C5BDCB-DA30-438F-8392-54D84C2AAF12

Q37892578-26559964-71DB-4861-93FF-479B1AE0719A

Q37892578-685DB7CF-FE3A-43A3-8E0A-258BD4C396A7

Q37892578-6CCC9F1B-ED13-4B16-928B-57BDCBE44B86

Q37892578-7A0A4489-2D3E-4459-BAC9-C70099011EA5

Q37892578-7A32F590-D292-41DD-8DE9-60F87A2D76AA

P304

Q37892578-FE50F973-8183-4B8B-AF21-15A3505D4E78

P31

Q37892578-FC9AD1A5-D0E7-4211-9721-267771858D2A

P356

Q37892578-BBB14537-63E2-4C51-825A-B9E2DEB88050

P433

Q37892578-E5477783-202B-45F1-8C5E-6DD138C39B47

P478

Q37892578-4181717C-EC8C-4E06-A9FC-E9AD86BE1E50

P50

Q37892578-58BCC775-492A-4DDA-B97B-EEF66474152F

P577

Q37892578-C8919570-0666-4FE6-A3FA-69FA434227C3

P698

Q37892578-F3219497-8511-4A31-9FA0-6CB4CD15C463

P356

P1433

Expert Review of Vaccines

P1476

CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer

@en

P2093

Deborah A Bradley

http://www.w3.org/2001/XMLSchema#string

Jennifer A Green

http://www.w3.org/2001/XMLSchema#string

Michael A Morse

http://www.w3.org/2001/XMLSchema#string

Robert J Laliberte

http://www.w3.org/2001/XMLSchema#string

Thomas A Davis

http://www.w3.org/2001/XMLSchema#string

Tibor Keler

http://www.w3.org/2001/XMLSchema#string

P2860

Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

In search of the 'missing self': MHC molecules and NK cell recognition

A Novel Human Cancer Vaccine Elicits Cellular Responses to the Tumor-Associated Antigen, Human Chorionic Gonadotropin

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration.

Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration.

BCG immunotherapy of bladder cancer: 20 years on.

Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117.

Recent advances in contraceptive vaccine development: a mini-review.

Role of the mannose receptor in the immune response.

P304

733-742

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERV.11.20

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21692696

http://www.w3.org/2001/XMLSchema#string